PMID- 34536208
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211030
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 11
DP  - 2021 Nov
TI  - Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 
      Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week 
      Results from a Prospective Observational Study.
PG  - 2907-2920
LID - 10.1007/s13300-021-01148-1 [doi]
AB  - INTRODUCTION: The aim of this study was to assess the efficacy and safety of 
      switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors 
      in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite 
      treatment with a stable dose of other DPP-4 inhibitors. METHODS: Patients with 
      glycosylated hemoglobin (HbA1c) >/= 7% despite taking DPP-4 inhibitors other than 
      teneligliptin, with or without other antidiabetic agents, for at least 3 months 
      were enrolled in this study. Patients on DPP-4 inhibitors administered prior to 
      participation in this study were switched to 20 mg teneligliptin once daily and 
      the dose was maintained for the 52-week study period. The primary endpoint was 
      the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid 
      profile were also evaluated. Adverse events were monitored for safety assessment. 
      RESULTS: At weeks 12, 24, and 52, the HbA1c values significantly decreased by - 
      0.39, - 0.44, and - 0.52%, respectively, compared to the baseline value 
      (p < 0.0001); in addition, 56.3, 60.3, and 62.3% of patients, respectively, 
      achieved decreases in HbA1c of at least 0.3%, and 40.1, 46.5, and 52.4% of 
      patients, respectively, achieved decreases in HbA1c of at least 0.5%. The 
      proportion of the patient population achieving HbA1c < 7.0% increased throughout 
      the study period, reaching 30.4, 35.4, and 36.9% at weeks 12, 24, and 52, 
      respectively; at these same time points, the percentage of patients achieving 
      HbA1c < 6.5% increased to 9.5, 11.9, and 13.2% of the total study population. FPG 
      levels and lipid parameters were also significantly decreased after teneligliptin 
      treatment. There were no significant safety concerns. CONCLUSION: Our results 
      suggest the significant glucose-lowering effect of teneligliptin after switching 
      from other DPP-4 inhibitors in patients with T2DM. The improvement in glycemic 
      control was maintained for up to 52 weeks without safety concerns.
CI  - (c) 2021. The Author(s).
FAU - Kim, Hae Jin
AU  - Kim HJ
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      San 5, Woncheon-dong, Yeongtong-gu, Suwon, 443-721, South Korea.
FAU - Kim, Young Sik
AU  - Kim YS
AD  - Department of Family Medicine, University of Ulsan College of Medicine, Seoul, 
      South Korea.
FAU - Lee, Chang Beom
AU  - Lee CB
AD  - Department of Internal Medicine, Hanyang University College of Medicine, Guri, 
      South Korea.
FAU - Choi, Moon-Gi
AU  - Choi MG
AD  - Department of Internal Medicine, College of Medicine, Hallym University, 
      Chuncheon, South Korea.
FAU - Chang, Hyuk-Jae
AU  - Chang HJ
AD  - Department of Cardiology, Yonsei University College of Medicine, Seoul, South 
      Korea.
FAU - Kim, Soo Kyoung
AU  - Kim SK
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine, Jinju, South Korea.
FAU - Yu, Jae Myung
AU  - Yu JM
AD  - Department of Internal Medicine, Hallym University College of Medicine, Seoul, 
      South Korea.
FAU - Kim, Tae Ho
AU  - Kim TH
AD  - Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea.
FAU - Lee, Ji Hyun
AU  - Lee JH
AD  - Department of Internal Medicine, Catholic University of Daegu, Daegu, South 
      Korea.
FAU - Ahn, Kyu Jeung
AU  - Ahn KJ
AD  - Department of Endocrinology and Metabolism, Kyung Hee University School of 
      Medicine, Seoul, South Korea.
FAU - Min, Kyung Wan
AU  - Min KW
AD  - Department of Internal Medicine, Eulji University School of Medicine, Seoul, 
      South Korea.
FAU - Kyung, Eun Jung
AU  - Kyung EJ
AD  - Medical Affairs, Handok Inc, Seoul, South Korea.
FAU - Kim, Yeo Kyeong
AU  - Kim YK
AD  - Medical Affairs, Handok Inc, Seoul, South Korea.
FAU - Lee, Kwan Woo
AU  - Lee KW
AUID- ORCID: 0000-0002-7965-9662
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      San 5, Woncheon-dong, Yeongtong-gu, Suwon, 443-721, South Korea. 
      lkw65@ajou.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20210918
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8519978
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Dipeptidyl peptidase IV inhibitors
OT  - Teneligliptin
EDAT- 2021/09/19 06:00
MHDA- 2021/09/19 06:01
PMCR- 2021/09/18
CRDT- 2021/09/18 12:10
PHST- 2021/07/07 00:00 [received]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/09/19 06:00 [pubmed]
PHST- 2021/09/19 06:01 [medline]
PHST- 2021/09/18 12:10 [entrez]
PHST- 2021/09/18 00:00 [pmc-release]
AID - 10.1007/s13300-021-01148-1 [pii]
AID - 1148 [pii]
AID - 10.1007/s13300-021-01148-1 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Nov;12(11):2907-2920. doi: 10.1007/s13300-021-01148-1. Epub 
      2021 Sep 18.